Several phase 3 clinical trials involving T-DXd and other commonly used chemical drugs have been conducted, and the results suggest the therapeutic potential and advantages of T-DXd in treating HER2-low breast cancer. The gene discussed is ERBB2; the disease is breast carcinoma.